https://www.bmj.com/content/379/bmj.o2690
0
0
Covid-19: Evusheld protects the most vulnerable patients, analysis shows - The BMJ
11/8/22 at 4:21pm
Organization
The BMJ
Authors
The antibody drug Evusheld is effective for protecting clinically extremely vulnerable people from covid-19, including its omicron variants, a preprint study has reported.1 The prophylactic treatment, manufactured by AstraZeneca, is a combination of two long…
Create an account or login to join the discussion